ArticleGynecologic oncology reports2025
Surgical staging identifies occult metastases in over 50% of uterine-confined carcinosarcoma.
Article in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Endometrial carcinosarcoma presenting with a solitary breast metastasis - A rare case report.Gynecologic oncology reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Objective: To evaluate and define the proportion of clinically stage I Uterine Carcinosarcoma (UCS) patients who are upstaged to FIGO stages II-IVB following primary surgery based on final pathology. Methods: We performed a retrospective review of patients diagnosed and treated for UCS at our institution from 2009 to 2023. All patients who underwent primary surgery for UCS and had clinically stage I (uterine-confined) disease were included. Uterine-confined disease was determined based on pre-operative physical exam and imaging. The primary outcome was the proportion of patients who were upstaged after surgery. Results: Ninety-eight patients underwent primary surgery with a median age of 64 years (IQR 59-68). Twenty-six patients (26.6 %) had suspected extra-uterine disease based on pre-operative evaluation and were excluded. Seventy-two patients (73.4 %) had uterine-confined disease based on pre-operative exam/imaging and underwent staging surgery. Of the 72 patients with clinical stage I disease, 39 patients (54.2 %) were ultimately diagnosed with advanced disease (FIGO Stages II-IVB), while 33 patients (45.8 %) had confirmed early-stage disease on final pathology (FIGO Stages IA or IB). Surgical staging revealed the following: 15.4 % (n = 6) were upstaged to Stage II, 5.1 % (n = 2) to Stage IIIA, 5.1 % (n = 2) to Stage IIIB, 35.9 % (n = 14) to Stage IIIC1, 12.8 % (n = 5) Stage IIIC2, and 25 % (n = 10) to Stage IVB. Conclusion: More than 50% of patients with pre-operative "uterine-confined" carcinosarcoma were upstaged on final pathology, mostly commonly to Stage III. Our findings underscore the importance of surgical staging since upstaging carries critical prognostic information and implications for adjuvant treatment planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.